Colm O'Rourke

Translational (epi)genomics in chemoresistance & metastasis of hepatobiliary cancers.

[Journal of Experimental Medicine @JExpMed]

Ward, Kar, Balan, and Bhardwaj @BhardwajLab review how conventional type 1 #DendriticCells (cDC1s) coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. https://t.co/A77oF770ZS

#CancerFocus #Immunotherapy

[Rob Manguso @MangusoLab]

Excited to share out latest work, out this week in @NatureGenet . In this study, we using CRISPR screens to explore how sensing inflammatory cytokines exposes new tumor-intrinsic dependencies.
@broadinstitute @MGBResearchNews

https://t.co/GDeVFJUDcn

[Erman Akkus @Erman_Akkus]

🟧Localized Rectal Cancer- ESMO 2025 guideline summary

#cancer #oncology #MedX #rectal @OncoAlert

[BMJ Oncology @BMJOncology]

The concept of oligometastatic disease has reshaped the management paradigm for many solid tumours because some patients may achieve long-term disease control or even cure with aggressive local therapy. https://t.co/ZcVhOeq7dP

[Journal of Experimental Medicine @JExpMed]

#Myeloid diversity in tumors: shaped by genes, location, and time. Review by Maria Nogales-Pons, Mariola Munárriz-Paños, Teresa Aceña-Gonzalo, & María Casanova-Acebes @Casanova_Acebes: https://t.co/jjWBCjZ9UX

📘 Part of JEM #Cancer Collection: https://t.co/YPWs2KQyqx
#EACR2026

[Erman Akkus @Erman_Akkus]

Next generation sequencing of circulating tumor DNA for precision medicine in patients with advanced biliary tract cancers | Clinical Cancer Research | American Association for Cancer Research https://t.co/50Rpuv5zHu

[Dr Rishabh Jain @DrRishabhOnco]

🚨 Is tumor type really the best predictor of long-term benefit from immunotherapy?

Maybe not.

In a nationwide cohort of 2,127 responders to PD-1/PD-L1 blockade across melanoma, RCC, and NSCLC:

✅ Complete responders (CR) had dramatically better outcomes than partial responders (PR)
✅ Response depth was the strongest predictor of progression risk
✅ Tumor type added surprisingly little prognostic information once response depth was known

📊 5-year PFS:

🔹 Melanoma
CR 74% vs PR 19%

🔹 RCC
CR 68% vs PR 24%

🔹 NSCLC
CR 67% vs PR 19%

After propensity-score matching, PFS curves were nearly superimposable across tumor types.

💡 The implication:
For patients who respond to PD-1/PD-L1 blockade, how deep the response is may matter more than where the cancer started.

This raises an important question:

Should future immunotherapy trials focus less on tumor-specific surveillance and more on strategies that convert PR → CR?

🔖 Worth saving for anyone interested in immunotherapy durability and acquired resistance.

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #Immunotherapy #Melanoma

@OncoAlert @myesmo @esmo_open @ASCO

[Hidehito HORINOUCHI @HHorinouchi]

🔥The impact of aging on antitumor immunity and cancer immunotherapy
🆙 @trendscancer
☑Aging drives thymic involution, chronic inflammation & immune dysfunction
🎯Age-associated immune remodeling modulates ICI response
🎙Dr. Claudia Cifuentes Caballero
@OncoAlert @Larvol
https://t.co/wciXOpPlEC

[Nature Rev Immunol @NatRevImmunol]

The immune engram: a spatial model of immunological memory https://t.co/b51nJMbBBU

[Cancer Cell @Cancer_Cell]

Online Now: Clonal lineage tracing of innate immune cells in human cancer https://t.co/WGr0Z5rQ4Q

[Dr Amol Akhade @SuyogCancer]

The NHS-Galleri trial reportedly failed its primary endpoint—a sobering reminder from @SullivanProf
and Dr Christopher Booth in this editorial at @JAMA_current
that technological elegance is no substitute for proven patient benefit. 🙂👇 @oncology_bg
https://t.co/SBy5n16VQf

[Pashtoon Kasi MD, MS @pashtoonkasi]

🆕@JCOPO_ASCO
💡Such a beautiful story of real world🌎 precision medicine.

Meet➡️#ERRFI1🎯

📝Time to add➕this to ACTIONABLE Biomarkers🔐for #cholanagiocarcinoma @curecc. @NCCN

👇🏽Patient in paper, I took off hospice to give Erlotinib💊.

@OncoAlert

🔗https://t.co/09PD5QHv0s

[Toni Choueiri, MD @DrChoueiri]

Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.

Astonishing translational work !

https://t.co/EvUmIGVLgs

[Ansu Satpathy @Satpathology]

A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR.
@vincentzliu and @CalebLareau solved it!
We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry.
@10xGenomics @parkerici @CancerResearch @TheMarkFdn
https://t.co/Y37qbyw3F5

[Aaron Rupar @atrupar]

i know the White House thinks it's cute that nobody in the administration has real responsibilities beyond fluffing the president on TV, but that disaster of a press briefing by Dr Oz is a reminder that it's actually good to know what you're talking about

[Keith Richards @officialKeef]

It's Charlie's birthday! Missing him!

[Science Immunology @SciImmunology]

A new Science #Immunology Review delves into the transcriptional and #epigenetic regulatory mechanisms that shape #macrophage identity and function in health and disease. https://t.co/MYOZv9Edxy

[The Rolling Stones @RollingStones]

Thanks Macca! ❤️

[Eytan Ruppin, MD, PhD @EytanRuppin]

🚨 Our pre-proof is out on @Annals_Oncology!

BRIDGE, a framework to quantify intratumoral subtype mixtures in #BreastCancer and predict neoadjuvant response, including directly from H&E slides

Paper: https://t.co/VxSklz9oVH

🧵1/11

[Linghua Wang, MD, PhD @IamLinghua]

1/ Thrilled to share our new paper, out today in @ScienceMagazine! We built a pan-cancer spatial atlas of tertiary lymphoid structures (TLSs) and developed computation and AI frameworks to study TLS biology at scale.
https://t.co/zgcBnnm7Rl